 |
05-May-08: Insilicos Awarded Grant for Life Science Computing 03-Apr-08: Insilicos Wins NIH Grant for Manufacturing 14-Jan-08: Insilicos Heart Disease Project Wins Research Funding 30-Aug-07: Insilicos Awarded $1 Million Grant for Biotech Services 30-Apr-07: Insilicos Names Heinecke to Chief Medical Advisor Post 22-Sep-06: Insilicos and GeneBio Sign Global Distribution Agreement 29-May-06: Insilicos Announces Breakthrough Proteomics Software Platform 28-Mar-06: Insilicos Announces 1000th Licensed User of InsilicosViewer 13-Mar-06: Insilicos Awarded Grant to Study Heart Disease 14-Feb-06: Insilicos CEO Erik Nilsson Interviewed 06-Feb-06: Insilicos Awarded Grant to Commercialize Proteomics Research 14-Sep-05: Insilicos announces support for biotech data format 31-Aug-05: Insilicos Announces Web Support for Biotech Tools 08-Jul-05: Insilicos appoints Teresa Skarr as Director of Regulatory Affairs 04-Jun-05: Insilicos Announces 500th Licensed User of InsilicosViewer 27-Apr-05: Insilicos Presents at Invest Northwest 31-Mar-05: Insilicos releases new version of viewer 23-Feb-05: Insilicos Awarded Proteomics Grant 14-Dec-04: Ruedi Aebersold joins Insilicos Advisory Board 01-Sep-04: InsilicosViewer in the News 15-Apr-04: Insilicos Wins NIH Grant 13-Oct-03: Insilicos Releases Beta 26-Jun-03: Insilicos Wins Grant 30-Sep-02: Insilicos Platform Project Announced
| |
Seattle, 15 April, 2004:
Insilicos today announced that the National Institute of General Medical Sciences
has awarded Insilicos an SBIR grant to apply Insilicos' proprietary extreme pattern recognition (XPR)
techniques to single-cell proteomics. Insilicos President Erik Nilsson is PI on the grant.
In collaboration with
Dr. Norman Dovichi's Laboratory
at the University of Washington, Insilicos will apply XPR to the proteomes
of individual Barrett's esophagus cells. Results of this research may have application
to drug discovery, disease diagnosis, and basic research into mechanisms of cell maturation and dysplasia.
"Cell-resolution proteomics is a promising technique for exploring cellular mechanisms," said Nilsson.
"But realizing this promise requires breakthrough instrumentation such as the Dovichi lab has developed, and
breakthrough computational analysis, such as Insilicos' XPR."
"We're pleased to find people in the NIH who share our enthusiasm for this research," said Brian Pratt,
Insilicos VP Development. "XPR is a remarkable technique for studying very large data sets, which opens a new
window into molecular biology"Insilicos LLC develops life science software for pharmaceutical development, biological research and clinical diagnostics.
For more information, visit the Insilicos web site www.insilicos.com or contact Insilicos at info@insilicos.com. 'Insilicos' and 'Life Science Software' are trademarks of Insilicos LLC.
|
|
